We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 45.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
101
DELISTED
Dermira, Inc.
DERM
$1.53M 0.01%
100,000
– –
OSUR icon
102
OraSure Technologies
OSUR
$268M
$1.5M 0.01%
229,397
-5,267
-2% -$43.7K
ALDX icon
103
Aldeyra Therapeutics
ALDX
$91.7M
$1.45M 0.01%
+142,000
New +$1.45M
RIGL icon
104
Rigel Pharmaceuticals
RIGL
$857M
$1.27M 0.01%
35,719
-12,478
-26% -$342K
LOXO
105
DELISTED
Loxo Oncology, Inc
LOXO
$1.25M 0.01%
100,000
– –
ALNY icon
106
Alnylam Pharmaceuticals
ALNY
$31.6B
$1.18M 0.01%
11,340
-260
-2% -$26.3K
XLRN
107
DELISTED
Acceleron Pharma
XLRN
$1.09M 0.01%
28,765
– –
AKAO
108
DELISTED
Achaogen Inc
AKAO
$976K 0.01%
100,000
– –
MDGL icon
109
Madrigal Pharmaceuticals
MDGL
$11.9B
$949K 0.01%
13,973
-313
-2% -$26.8K
NBSE
110
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$941K 0.01%
+926
New +$3.06M
QURE icon
111
uniQure
QURE
$3.36B
$730K 0.01%
30,000
-672
-2% -$14.7K
FPRX
112
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$440K ﹤0.01%
19,247
-576
-3% -$14.5K
AEGR
113
DELISTED
Aegerion Pharmaceuticals
AEGR
$374K ﹤0.01%
+14,300
New +$364K
CCXI
114
DELISTED
ChemoCentryx, Inc.
CCXI
$370K ﹤0.01%
49,064
-936
-2% -$7.31K
APTO
115
DELISTED
Aptose Biosciences, Inc.
APTO
$181K ﹤0.01%
74
-991
-93% -$2.39M
BTX.WS
116
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$40K ﹤0.01%
20,084
-441
-2% -$591
ALBO
117
DELISTED
Albireo Pharma Inc
ALBO
$36K ﹤0.01%
+1,006
New +$42.4K
AKTX
118
Akari Therapeutics
AKTX
$15.3M
– –
-84
Closed -$3.23M
FOLD
119
DELISTED
Amicus Therapeutics
FOLD
– –
-481,697
Closed -$4.01M
GERN icon
120
Geron
GERN
$977M
– –
-402,629
Closed -$1.31M
MNK
121
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-46,666
Closed -$4.62M
SGYP
122
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-973,245
Closed -$2.97M
TSRO
123
DELISTED
TESARO, Inc.
TSRO
– –
-31,218
Closed -$1.16M
QLTI
124
DELISTED
QLT Inc
QLTI
– –
-1,535,863
Closed -$6.16M
SLXP
125
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-635,321
Closed -$73M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.